Diabetes stocks are surprise winners from Novo Nordisk’s Wegovy study, analysts say
November 13, 2023 at 12:45 PM EST
Eli Lilly also scores, analysts say, as trial results leave door open for Zepbound to top Wegovy’s benefits.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|